Australian-Singaporean regenerative medicine company Osteopore (ASX:OSX) has secured market approvals for its custom orthopaedic and cranial implants in Europe.
Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material. The polymer naturally dissolves to allow only natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants.
Osteopore has an exclusive distribution agreement with Zimmer Biomet for its unique 3D printing technology.
Osteopore CEO Dr Yujing Lim said, “Securing European approvals for our custom orthopaedic and cranial implants is in step with our strategy to improve access to our high-value solutions.
“Custom cranial implant approval creates an opportunity to deepen our relationship with Zimmer Biomet, who now has access to our off-the-shelf and custom implant offering.
“Our custom orthopaedic implants have already demonstrated transformational effects on patients in earlier publications.
“With EU MDR [European Union Medical Device Regulation] approval, Osteopore can now boost the reach of our orthopaedic and cranial implants in Europe,” said Dr Lim.